[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625252":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":11,"responsibleParty":33,"collaborators":11,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":11,"eligibilityCriteria":41,"healthyVolunteers":42,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":11,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":11,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":11},{"fullName":5,"class":6},"University of Delaware","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Estrogen","EXPERIMENTAL",null,[13],"Drug: Estrogen",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Estradiol patch (0.1mg) All women will use a GnRH antagonist for 8 days. Some women will receive an estradiol patch for to wear on days 3-8, whereas other women will receive a placebo patch to wear on days 3-8. Measurements of sympathetic activation will occur on days 6-8.",[9],{"type":6,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"All women will use a GnRH antagonist for 8 days. Some women will receive an estradiol patch for to wear on days 3-8, whereas other women will receive a placebo patch to wear on days 3-8. Measurements of sympathetic activation will occur on days 6-8.",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Megan Wenner, PhD","CONTACT","13028317343","mwenner@udel.edu",{"type":34,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100625252","phase-4-menopausal-hormones-and-sympathetic-activation-100625252",false,"NCT07420218","Menopausal Hormones and Sympathetic Activation","Impact of FSH and Estradiol on Sympathetic Function in Menopausal Women","Inclusion Criteria:\n\n* Perimenopausal (based on changes in menstrual cycle)\n* Ages 40-58 years\n\nExclusion Criteria:\n\n* History of CVD, blood clots, stroke\n* History of Cancer\n* History of Liver or Kidney disease\n* History of Neurological disease\n* Diabetes\n* BMI\\>35kg\u002Fm2\n* Pregnant, planning on becoming pregnant, or breast feeding\n* Allergy to Latex\n* Use of Tobacco\n* Hysterectomy\n* Blood pressure \\>140\u002F90 mmHg\n* Current or prior use of hormone replacement therapy (within 3 mo)",true,"FEMALE","40 Years","58 Years",{"count":47,"type":48},80,"ESTIMATED","INTERVENTIONAL",[51],"PHASE4","The purpose of this study is to understand how changes in menopausal hormones like estradiol and follicle-stimulating hormone (FSH) impact sympathetic nervous system function. To do so, the investigators will use a medication to control the production of estradiol and FSH, and in some participants, add-back estradiol to isolate its effects. The investigators will measure sympathetic activation centrally (in the brain using MRI), peripherally in the nervous system, and also examine adrenergic receptor mediated control of vascular function.",[54],"Perimenopausal Women","NOT_YET_RECRUITING","2026-03-25",{"date":58,"type":59},"2026-03-27","ACTUAL",{"date":61,"type":48},"2026-09-01",{"date":63,"type":48},"2030-12-31",{"name":5,"class":6}]